ARNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Arena Pharmaceuticals's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arena Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Arena Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | |
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Arena Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Arena Pharmaceuticals's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Arena Pharmaceuticals's E10 for the quarter that ended in Dec. 2021 is calculated as:
For example, Arena Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2021 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Dec. 2021 (Change) | * | Current CPI (Dec. 2021) |
= | -2.54 | / | 117.6295 | * | 117.6295 | |
= | -2.540 |
Current CPI (Dec. 2021) = 117.6295.
Arena Pharmaceuticals Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201203 | -1.800 | 96.783 | -2.188 |
201206 | -1.200 | 96.819 | -1.458 |
201209 | -0.700 | 97.633 | -0.843 |
201212 | -1.000 | 96.871 | -1.214 |
201303 | -0.900 | 98.209 | -1.078 |
201306 | 1.800 | 98.518 | 2.149 |
201309 | -0.800 | 98.790 | -0.953 |
201312 | -1.100 | 98.326 | -1.316 |
201403 | -1.200 | 99.695 | -1.416 |
201406 | 0.300 | 100.560 | 0.351 |
201409 | -0.500 | 100.428 | -0.586 |
201412 | -1.500 | 99.070 | -1.781 |
201503 | -1.000 | 99.621 | -1.181 |
201506 | -1.100 | 100.684 | -1.285 |
201509 | -1.100 | 100.392 | -1.289 |
201512 | -1.300 | 99.792 | -1.532 |
201603 | -0.900 | 100.470 | -1.054 |
201606 | -1.120 | 101.688 | -1.296 |
201609 | -0.510 | 101.861 | -0.589 |
201612 | 1.600 | 101.863 | 1.848 |
201703 | -0.900 | 102.862 | -1.029 |
201706 | -0.770 | 103.349 | -0.876 |
201709 | -0.860 | 104.136 | -0.971 |
201712 | -0.350 | 104.011 | -0.396 |
201803 | -0.800 | 105.290 | -0.894 |
201806 | -0.650 | 106.317 | -0.719 |
201809 | -0.700 | 106.507 | -0.773 |
201812 | 1.350 | 105.998 | 1.498 |
201903 | 12.100 | 107.251 | 13.271 |
201906 | -1.240 | 108.070 | -1.350 |
201909 | -1.460 | 108.329 | -1.585 |
201912 | -1.760 | 108.420 | -1.909 |
202003 | -2.000 | 108.902 | -2.160 |
202006 | -1.610 | 108.767 | -1.741 |
202009 | -1.690 | 109.815 | -1.810 |
202012 | -2.100 | 109.897 | -2.248 |
202103 | -1.980 | 111.754 | -2.084 |
202106 | -2.400 | 114.631 | -2.463 |
202109 | -3.210 | 115.734 | -3.263 |
202112 | -2.540 | 117.630 | -2.540 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Arena Pharmaceuticals (NAS:ARNA) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Arena Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Amit Munshi | director, officer: President and CEO | C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116 |
Robert Lisicki | officer: EVP, Chief Commercial Officer | C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Dallas Jayson Donald Alexander | director | AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005 |
Vincent Aurentz | officer: Executive VP and CBO | C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Tina Susan Nova | director | C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Christopher Cabell | officer: EVP, Head of R&D, and CMO | C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Manmeet Singh Soni | director | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085 |
Kieran Gallahue | director | PO BOX 684369, PARK CITY UT 84068 |
Katharine Knobil | director | C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421 |
Jennifer Jarrett | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Garry Arthur Neil | director | 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104 |
Oliver Fetzer | director | AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355 |
Laurie Stelzer | officer: EVP & Chief Financial Officer | 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Joan Schmidt | officer: EVP, General Counsel & Sec | C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 |
Kevin Robert Lind | officer: Executive VP and CFO | C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
From GuruFocus
By PRNewswire PRNewswire • 12-28-2021
By Business Wire Business Wire • 02-23-2022
By PRNewswire PRNewswire • 12-13-2021
By GuruFocus Research GuruFocus Editor • 05-11-2022
By PRNewswire PRNewswire • 01-13-2022
By PRNewswire PRNewswire • 01-19-2022
By Business Wire Business Wire • 02-17-2022
By GuruFocusNews GuruFocusNews • 12-20-2021
By GuruFocusNews GuruFocusNews • 12-16-2021
By PRNewswire PRNewswire • 12-20-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.